The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions
Open accessAbstract
Transfusions can be a life-saving treatment of patients with sickle-cell disease (SCD). However, availability of matched units can be limiting because of distinctive blood group polymorphisms in patients of African descent. Development of antibodies against the transfused red blood cells (RBCs), resulting in delayed hemolytic transfusion reactions (DHTRs), can be life-threatening and pose unique challenges for this population with regard to treatment strategies and transfusion management protocols. In cases where the transfused cells and the patient’s own RBCs are destroyed, diagnosis of DHTR can be difficult because symptoms may mimic vaso-occlusive crisis, and frequently, antibodies are undetectable. Guidelines are needed for early diagnosis of DHTR because treatment may need to include temporarily withholding any new transfusions to avoid further hemolysis. Also needed are case-control studies to optimally tailor treatments based on the severity of DHTR and develop preventive transfusion strategies for patients at DHTR risk. Here, we will review gaps in knowledge and describe through case studies our recommended approach to prevent alloimmunization and to diagnose and treat symptomatic DHTRs for which complementary mechanistic studies to understand their pathogenesis are sorely needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adams, R. J., McKie, V. C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F. T., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807023390102 · Cited by 1,866
Gene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
Adisa, O. A., Hu, Y., Ghosh, S., Aryee, D., Osunkwo, I., & Ofori‐Acquah, S. F. (2013) · British Journal of Haematology · doi:10.1111/bjh.12445 · Cited by 88
HO-1hi patrolling monocytes protect against vaso-occlusion in sickle cell disease
Liu, Y., Jing, F., Yi, W., Mendelson, A., Shi, P., Walsh, R., Friedman, D. F., Minniti, C., Manwani, D., Chou, S. T., et al. (2018) · Blood · doi:10.1182/blood-2017-12-819870 · Cited by 51
Self-citation
Cited by
American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support
Chou, S. T., Alsawas, M., Fasano, R. M., Field, J. J., Hendrickson, J. E., Howard, J., Kameka, M., Kwiatkowski, J. L., Pirenne, F., Shi, P. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001143 · Cited by 497
Self-citation
Metadata
- Authors
- Pirenne, F., & Yazdanbakhsh, K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2018-06-21
- Volume
- 131
- Issue
- 25
- Pages
- 2773-2781
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2801072243
- Cited by
- 170
- References
- 4
- FWCI
- 9.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. https://app.cochat.ai/papers/10.1182/blood-2018-02-785964
- The paper
- Pirenne, F., & Yazdanbakhsh, K. (2018). How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood. https://doi.org/10.1182/blood-2018-02-785964
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.